首页> 外文期刊>Infectious disorders drug targets >Linezolid Resistance in Staphylococcus haemolyticus - Case Series and Review of Literature Bentham Science
【24h】

Linezolid Resistance in Staphylococcus haemolyticus - Case Series and Review of Literature Bentham Science

机译:Linezolid Resistance in Staphylococcus haemolyticus - Case Series and Review of Literature Bentham Science

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Coagulase negative Staphylococci (CoNS) are important. The commonantibiotics used for the treatment of the infections caused by CoNS are penicillin, oxacillin, ciprofloxacin,clindamycin, erythromycin, gentamicin, and vancomycin. Linezolid is an oxazolidinonegroup of antibiotic with activity against Gram-positive bacteria. It is used for the treatment of seriousinfections caused by Gram-positive bacteria resistant to other antibiotics, including streptococci,vancomycin-resistant enterococci (VRE).Aims and Objective: This study emphasizes on the judicious use of newer antibiotics to containthe spread of resistance.Method: We are discussing five cases of Linezolid resistant Staphylococcus Haemolyticus whichwere reported in our laboratory during one year from patients with device related infections andalso review of literature is being presented for an update.Result: In our study, the isolates were resistant to other groups of antimicrobials but susceptible toglycopeptides. All the isolates were methicillin-resistant.Conclusion: Linezolid is approved as an alternative drug to be given for catheter-related bloodstreaminfections. In earlier studies, linezolid-resistant staphylococci have been reported increasinglyall over the world. This study is to create awareness amongst clinicians that improper andexcessive use of linezolid will make this antibiotic-resistant and thus will be of no help in future,so judicious and relevant use of antibiotics needs to be emphasized.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号